<DOC>
	<DOCNO>NCT02383212</DOCNO>
	<brief_summary>This phase 1 , open-label , multicenter , ascending-dose escalation study REGN2810 , alone combination anti-cancer therapy patient advanced malignancy .</brief_summary>
	<brief_title>Study REGN2810 ( Anti-PD-1 ) Patients With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Key 1 . Histologically cytologically confirm diagnosis malignancy demonstrate progression solid tumor ( nonlymphoma ) alternative standardofcare therapeutic option ( certain exception may apply ) . 2 . At least 1 measurable lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 criterion response assessment ( certain exception may apply ) 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Key 1 . Ongoing recent ( within 5 year ) evidence significant autoimmune disease require treatment systemic immunosuppressive treatment , may suggest risk immunerelated adverse event ( irAEs ) . The following exclusionary : vitiligo , childhood asthma resolve , residual hypothyroidism require hormone replacement psoriasis require systemic treatment . 2 . Prior treatment agent block program death1/ program deathligand 1 ( PD1/PDL1 pathway ) ( certain exception may apply ) 3 . Prior treatment immune modulate agent within few 4 week prior first dose REGN2810 . Examples immune modulate agent include blocker CTLA4 , 41BB ( CD137 ) , OX40 , therapeutic vaccine , cytokine treatment . 4 . Untreated brain metastasis ( es ) may consider active . Patients previously treat brain metastasis may participate provide stable ( ie , without evidence progression image least 6 week prior first dose study treatment , neurologic symptom return baseline ) , evidence new enlarge brain metastasis , patient require systemic corticosteroid management brain metastasis within 4 week prior first dose REGN2810 ( certain exception may apply ) . 5 . Immunosuppressive corticosteroid dos ( &gt; 10 mg prednisone daily equivalent ) within 4 week prior first dose REGN2810 The information provide intend contain consideration relevant potential participation clinical trial , therefore inclusion/ exclusion criterion list .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Advanced cancerous growth</keyword>
</DOC>